Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluoride + silica + isopropylmethylphenol is an experimental toothpaste formulation developed by GSK for the treatment and prevention of gingivitis. The formulation utilizes a silica-based abrasive system for mechanical plaque removal and fluoride (likely sodium fluoride) for the remineralization of tooth enamel and prevention of dental caries. A key active component is isopropylmethylphenol (IPMP, also known as o-Cymen-5-ol), an antimicrobial agent that targets oral bacteria to maintain gingival health and reduce inflammation. The development of this specific formulation was evaluated in a Phase 1 clinical trial designed to measure its efficacy over 24 weeks, though the study was ultimately withdrawn before completion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluoride + silica + isopropylmethylphenol.